Skip to main content
. 2019 Feb 26;8(3):200. doi: 10.3390/cells8030200

Figure 2.

Figure 2

Application of integral, integrated and explorative biomarker analysis in the ENGOT-OV-NOVA16 trial design. (gBRCA: germline BRCA; mut: mutated; HRD: homologous recombination deficiency).